Monthly
US$200
Billed every month
Sign in to subscribeMethylprednisolone Sodium Succinate for injection
Matched- Active ingredients (original)
- METHYLPREDNISOLONE SODIUM SUCCINATE
- Dosage form (original)
- INJECTABLE
- Route (original)
- INJECTION
Read these limits
- US patent expiration does not establish Chinese patent expiration. Dates here come from the US Orange Book; Chinese patent status needs separate checking.
- The Orange Book lists holder-submitted patents and does not cover all related patents.
- “Unmatched” means no English ingredient-name counterpart in the Chinese official-name sources loaded here; it does not mean no Chinese approval or filing. A zero count means a Chinese name is matched but no records were found in the loaded source. Source dates appear below.
- This page contains no sales or market-size data and cannot establish development value.
- Names on unmatched rows are the original FDA Orange Book names, without Chinese translation. The same ingredient may have a different generic name in China.
US-approved products
Application numbers, product numbers and original fields are retained. Marketing status is shown as listed in the source.
Earliest approvalApproved before 1982
ANDA applications48
RLD applicantPHARMACIA AND UPJOHN CO
Currently marketed products: 24 · Counts FDA prescription and OTC marketing categories as listed; discontinued or unknown categories are excluded.
| Application / product number | Brand name (original) | Applicant (original) | Dosage form (original) | Route (original) | Strength (original) | Earliest approval | RLD / RS | Marketing status (original) | Official source |
|---|---|---|---|---|---|---|---|---|---|
| A040583-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | FRESENIUS KABI USA LLC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2004/07/30 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A040583-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | FRESENIUS KABI USA LLC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2004/07/30 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A040612-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | FRESENIUS KABI USA LLC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 2004/08/12 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A040641-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | BEDFORD LABORATORIES | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2007/02/21 | N / N | DISCONTINUED | openFDA ↗ |
| A040641-003 | METHYLPREDNISOLONE SODIUM SUCCINATE | BEDFORD LABORATORIES | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 2007/02/21 | N / N | DISCONTINUED | openFDA ↗ |
| A040641-004 | METHYLPREDNISOLONE SODIUM SUCCINATE | BEDFORD LABORATORIES | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 2007/02/21 | N / N | DISCONTINUED | openFDA ↗ |
| A040662-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | BEDFORD LABORATORIES | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2007/02/21 | N / N | DISCONTINUED | openFDA ↗ |
| A040664-001 | A-METHAPRED | HOSPIRA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2005/12/20 | N / N | DISCONTINUED | openFDA ↗ |
| A040665-001 | A-METHAPRED | HOSPIRA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2005/12/20 | N / N | DISCONTINUED | openFDA ↗ |
| A040709-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | BEDFORD LABORATORIES | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 2007/02/21 | N / N | DISCONTINUED | openFDA ↗ |
| A040709-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | BEDFORD LABORATORIES | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 2007/02/21 | N / N | DISCONTINUED | openFDA ↗ |
| A040793-001 | A-METHAPRED | HOSPIRA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2008/11/25 | N / N | DISCONTINUED | openFDA ↗ |
| A040827-001 | A-METHAPRED | HOSPIRA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2008/11/25 | N / N | DISCONTINUED | openFDA ↗ |
| A040888-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | SAGENT PHARMACEUTICALS INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2011/07/18 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A040888-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | SAGENT PHARMACEUTICALS INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2011/07/18 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A040888-003 | METHYLPREDNISOLONE SODIUM SUCCINATE | SAGENT PHARMACEUTICALS INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 2011/07/18 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A040888-004 | METHYLPREDNISOLONE SODIUM SUCCINATE | SAGENT PHARMACEUTICALS INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 2011/07/18 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A040888-005 | METHYLPREDNISOLONE SODIUM SUCCINATE | SAGENT PHARMACEUTICALS INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 2GM BASE/VIAL | 2011/07/18 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A081266-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | TEVA PARENTERAL MEDICINES INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 1992/11/30 | N / N | DISCONTINUED | openFDA ↗ |
| A081267-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | TEVA PARENTERAL MEDICINES INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1992/11/30 | N / N | DISCONTINUED | openFDA ↗ |
| A081268-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | TEVA PARENTERAL MEDICINES INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1992/11/30 | N / N | DISCONTINUED | openFDA ↗ |
| A085852-001 | A-METHAPRED | HOSPIRA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| A085853-001 | A-METHAPRED | HOSPIRA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| A085854-001 | A-METHAPRED | HOSPIRA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| A085855-001 | A-METHAPRED | HOSPIRA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| A086906-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ELKINS SINN DIV AH ROBINS CO INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| A086906-002 | METHYLPREDNISOLONE | ELKINS SINN DIV AH ROBINS CO INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| A086906-003 | METHYLPREDNISOLONE | ELKINS SINN DIV AH ROBINS CO INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| A086906-004 | METHYLPREDNISOLONE | ELKINS SINN DIV AH ROBINS CO INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | Approved before 1982 | N / N | DISCONTINUED | openFDA ↗ |
| A086953-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | WATSON LABORATORIES INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 1982/07/22 | N / N | DISCONTINUED | openFDA ↗ |
| A087030-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | WATSON LABORATORIES INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 1982/07/22 | N / N | DISCONTINUED | openFDA ↗ |
| A087535-001 | METHYLPREDNISOLONE | ORGANON USA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1982/06/25 | N / N | DISCONTINUED | openFDA ↗ |
| A087535-002 | METHYLPREDNISOLONE | ORGANON USA INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1982/06/25 | N / N | DISCONTINUED | openFDA ↗ |
| A087812-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | INTERNATIONAL MEDICATION SYSTEMS LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 1983/02/09 | N / N | DISCONTINUED | openFDA ↗ |
| A087813-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | INTERNATIONAL MEDICATION SYSTEMS LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 1983/02/09 | N / N | DISCONTINUED | openFDA ↗ |
| A087851-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | INTERNATIONAL MEDICATION SYSTEMS LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1983/02/09 | N / N | DISCONTINUED | openFDA ↗ |
| A087852-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | INTERNATIONAL MEDICATION SYSTEMS LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1983/02/09 | N / N | DISCONTINUED | openFDA ↗ |
| A088523-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | WATSON LABORATORIES INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1984/07/24 | N / N | DISCONTINUED | openFDA ↗ |
| A088524-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | WATSON LABORATORIES INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1984/07/24 | N / N | DISCONTINUED | openFDA ↗ |
| A088676-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 1984/06/08 | N / N | DISCONTINUED | openFDA ↗ |
| A088677-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 1984/06/08 | N / N | DISCONTINUED | openFDA ↗ |
| A088678-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1984/06/08 | N / N | DISCONTINUED | openFDA ↗ |
| A088679-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1984/06/08 | N / N | DISCONTINUED | openFDA ↗ |
| A089143-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 1986/03/28 | N / N | DISCONTINUED | openFDA ↗ |
| A089144-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 1986/03/28 | N / N | DISCONTINUED | openFDA ↗ |
| A089173-001 | A-METHAPRED | HOSPIRA WORLDWIDE, INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1987/08/18 | N / N | DISCONTINUED | openFDA ↗ |
| A089174-001 | A-METHAPRED | HOSPIRA WORLDWIDE, INC | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1987/08/18 | N / N | DISCONTINUED | openFDA ↗ |
| A089186-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1986/03/28 | N / N | DISCONTINUED | openFDA ↗ |
| A089187-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1986/03/28 | N / N | DISCONTINUED | openFDA ↗ |
| A089188-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1986/03/28 | N / N | DISCONTINUED | openFDA ↗ |
| A089189-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | ABRAXIS PHARMACEUTICAL PRODUCTS | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1986/03/28 | N / N | DISCONTINUED | openFDA ↗ |
| A089573-001 | A-METHAPRED | ABBOTT LABORATORIES HOSP PRODUCTS DIV | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 1991/02/22 | N / N | DISCONTINUED | openFDA ↗ |
| A089574-001 | A-METHAPRED | ABBOTT LABORATORIES HOSP PRODUCTS DIV | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 1991/02/22 | N / N | DISCONTINUED | openFDA ↗ |
| A089575-001 | A-METHAPRED | ABBOTT LABORATORIES HOSP PRODUCTS DIV | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 1991/02/22 | N / N | DISCONTINUED | openFDA ↗ |
| A089576-001 | A-METHAPRED | ABBOTT LABORATORIES HOSP PRODUCTS DIV | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 1991/02/22 | N / N | DISCONTINUED | openFDA ↗ |
| A202691-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | HIKMA FARMACEUTICA PORTUGAL SA | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 2016/02/16 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A202691-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | HIKMA FARMACEUTICA PORTUGAL SA | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 2016/02/16 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A203125-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | HIKMA FARMACEUTICA PORTUGAL SA | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2022/09/26 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A203125-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | HIKMA FARMACEUTICA PORTUGAL SA | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2022/09/26 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A207549-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | AMNEAL EU LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2016/11/09 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A207549-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | AMNEAL EU LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2016/11/09 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A207667-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | EUGIA PHARMA SPECIALITIES LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2015/12/15 | N / N | DISCONTINUED | openFDA ↗ |
| A207667-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | EUGIA PHARMA SPECIALITIES LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2015/12/15 | N / N | DISCONTINUED | openFDA ↗ |
| A207667-003 | METHYLPREDNISOLONE SODIUM SUCCINATE | EUGIA PHARMA SPECIALITIES LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 2015/12/15 | N / N | DISCONTINUED | openFDA ↗ |
| A207667-004 | METHYLPREDNISOLONE SODIUM SUCCINATE | EUGIA PHARMA SPECIALITIES LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 2GM BASE/VIAL | 2015/12/15 | N / N | DISCONTINUED | openFDA ↗ |
| A212396-001 | METHYLPREDNISOLONE SODIUM SUCCINATE | TIANJIN KINGYORK PHARMACEUTICALS CO LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | 2021/04/20 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A212396-002 | METHYLPREDNISOLONE SODIUM SUCCINATE | TIANJIN KINGYORK PHARMACEUTICALS CO LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | 2021/04/20 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A212396-003 | METHYLPREDNISOLONE SODIUM SUCCINATE | TIANJIN KINGYORK PHARMACEUTICALS CO LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | 2021/04/20 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A212396-004 | METHYLPREDNISOLONE SODIUM SUCCINATE | TIANJIN KINGYORK PHARMACEUTICALS CO LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | 2021/04/20 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A212396-005 | METHYLPREDNISOLONE SODIUM SUCCINATE | TIANJIN KINGYORK PHARMACEUTICALS CO LTD | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 2GM BASE/VIAL | 2021/04/20 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N011856-003 | SOLU-MEDROL | PHARMACIA AND UPJOHN CO | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 40MG BASE/VIAL | Approved before 1982 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N011856-004 | SOLU-MEDROL | PHARMACIA AND UPJOHN CO | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 125MG BASE/VIAL | Approved before 1982 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N011856-005 | SOLU-MEDROL | PHARMACIA AND UPJOHN CO | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 500MG BASE/VIAL | Approved before 1982 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N011856-006 | SOLU-MEDROL | PHARMACIA AND UPJOHN CO | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 1GM BASE/VIAL | Approved before 1982 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N011856-007 | SOLU-MEDROL | PHARMACIA AND UPJOHN CO | INJECTABLE | INJECTION | METHYLPREDNISOLONE SODIUM SUCCINATE: EQ 2GM BASE/VIAL | 1985/02/27 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
Listed US patents
*PED rows, substance/product flags, use codes and delisting-request flags are retained without determining legal effect.
Latest listed patent expiration—
Substance patent expiration (DS flag)—
This column includes only source rows explicitly flagged DS. A PED row without that flag is not assigned one by this site.
| Application / product number | Patent number | Listed expiration | Substance / product flags | Use code | Delisting request | Official source |
|---|---|---|---|---|---|---|
| Not listed | ||||||
Exclusivity source records
FDA exclusivity code list ↗Latest exclusivity expiration: —
| Application / product number | Exclusivity code | Listed expiration | Official source |
|---|---|---|---|
| Not listed | |||
Chinese record details
Chinese product landscape ↗The four-zero filter applies only to matched rows: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. Unmatched rows have no Chinese counts. Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Catalog holders 11
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Changzhou Si Yao Pharmaceutical Co., Ltd. romanized | 国药准字H20173357See source | 2025/12/11 | Official source ↗ |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H20247165See source | 2024/07/15 | Official source ↗ |
| Han Hui Pharmaceutical Co., Ltd. romanized | 国药准字H2023717240mg | 2023/12/11 | Official source ↗ |
| Han Hui Pharmaceutical Co., Ltd. romanized | 国药准字H20237173500mg | 2023/12/11 | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20237074See source | 2023/07/05 | Official source ↗ |
| Hainan He Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20233369See source | 2023/03/24 | Official source ↗ |
| Hainan He Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20233368See source | 2023/03/24 | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20183041See source | 2023/02/23 | Official source ↗ |
| Chongqing Lai Mei Pharma Co., Ltd. romanized | 国药准字H20203329See source | 2022/01/30 | Official source ↗ |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20143136See source | 2021/10/11 | Official source ↗ |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H20103047See source | 2021/05/31 | Official source ↗ |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20153195See source | 2021/05/25 | Official source ↗ |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H20217036See source | 2021/05/10 | Official source ↗ |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H20123319See source | 2021/05/10 | Official source ↗ |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H20217037See source | 2021/05/10 | Official source ↗ |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H20217038See source | 2021/05/10 | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20040845See source | 2021/04/16 | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20010098See source | 2021/04/16 | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20030727See source | 2021/04/16 | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20040844See source | 2021/04/16 | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20070007See source | 2021/04/16 | Official source ↗ |
| Liaoning Hai Si Ke Pharmaceutical Co., Ltd. romanized | 国药准字H20133233See source | 2021/03/26 | Official source ↗ |
| Liaoning Hai Si Ke Pharmaceutical Co., Ltd. romanized | 国药准字H20133234See source | 2021/03/26 | Official source ↗ |
| PFIZER SA | H2017019740mg | 1988/09/01 | Official source ↗ |
| PFIZER SA | H20170199500mg | 1988/09/01 | Official source ↗ |
NHSA approval numbers 34
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H20247165See source | — | Official source ↗ |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H20103047See source | — | Official source ↗ |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20153195See source | — | Official source ↗ |
| Chongqing Lai Mei Pharma Co., Ltd. romanized | 国药准字H20203329See source | — | Official source ↗ |
| Changzhou Si Yao Pharmaceutical Co., Ltd. romanized | 国药准字H20173357See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20040845See source | — | Official source ↗ |
| Hainan He Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20233368See source | — | Official source ↗ |
| Liaoning Hai Si Ke Pharmaceutical Co., Ltd. romanized | 国药准字H20133233See source | — | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20183040See source | — | Official source ↗ |
| Han Hui Pharmaceutical Co., Ltd. romanized | 国药准字H2023717240mg | — | Official source ↗ |
| PFIZER SA | H20170199500mg | — | Official source ↗ |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H20103047See source | — | Official source ↗ |
| Chongqing Lai Mei Pharma Co., Ltd. romanized | 国药准字H20203329See source | — | Official source ↗ |
| Changzhou Si Yao Pharmaceutical Co., Ltd. romanized | 国药准字H20173357See source | — | Official source ↗ |
| Hainan He Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20233368See source | — | Official source ↗ |
| Liaoning Hai Si Ke Pharmaceutical Co., Ltd. romanized | 国药准字H20133233See source | — | Official source ↗ |
| Jin Yao He Ping (Tianjin) Pharmaceutical Co., Ltd. romanized | 国药准字H20103047See source | — | Official source ↗ |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20143136See source | — | Official source ↗ |
| Chongqing Lai Mei Pharma Co., Ltd. romanized | 国药准字H20203238See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20040844See source | — | Official source ↗ |
| Hainan He Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20233369See source | — | Official source ↗ |
| Liaoning Hai Si Ke Pharmaceutical Co., Ltd. romanized | 国药准字H20133234See source | — | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20183039See source | — | Official source ↗ |
| Han Hui Pharmaceutical Co., Ltd. romanized | 国药准字H20237173500mg | — | Official source ↗ |
| PFIZER SA | H2017019740mg | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | HC20150041250mg | — | Official source ↗ |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20143136See source | — | Official source ↗ |
| Chongqing Lai Mei Pharma Co., Ltd. romanized | 国药准字H20203238See source | — | Official source ↗ |
| Hainan He Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20233369See source | — | Official source ↗ |
| Liaoning Hai Si Ke Pharmaceutical Co., Ltd. romanized | 国药准字H20133234See source | — | Official source ↗ |
| PFIZER SA | 国药准字HJ2017019740mg | — | Official source ↗ |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20143136See source | — | Official source ↗ |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20153195See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20030727See source | — | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20183041See source | — | Official source ↗ |
| PFIZER NV/SA | 国药准字HJ20170199500mg | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | HC20150042500mg | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20030727See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20030727See source | — | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20183041See source | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | HC2016003940mg | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20040844See source | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | HC2016003940mg | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | 国药准字HC2016003940mg | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | 国药准字HC2016003940mg | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20040845See source | — | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20183040See source | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | 国药准字HC20150040See source | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | 国药准字HC20150040See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20010098See source | — | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20183039See source | — | Official source ↗ |
| Nang Kuang Pharmaceutical Co., Ltd | 国药准字HC20150041See source | — | Official source ↗ |
| Nang Kuang Pharmaceutical Co., Ltd | 国药准字HC20150041See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20070007See source | — | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20237074See source | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | 国药准字HC20150042See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20070007See source | — | Official source ↗ |
| Fu An Pharma Group Hubei Ren Min Pharmaceutical Co., Ltd. romanized | 国药准字H20237074See source | — | Official source ↗ |
| Nan Guang Chemical Pharmaceutical Co., Ltd. romanized | 国药准字HC20150042See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20070007See source | — | Official source ↗ |
| Tianjin Jin Yao Pharma Co., Ltd. romanized | 国药准字H20123319See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20070007See source | — | Official source ↗ |
| Guo Yao Group Rong Sheng Pharmaceutical Co., Ltd. romanized | 国药准字H20070007See source | — | Official source ↗ |
Under review 12
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Nanjing Huang Long Bio Technology Co., Ltd. romanized; Ma An Shan Feng Yuan Pharmaceutical Co., Ltd. romanized | CYHS2601437 | 2026/06/17 | Official source ↗ |
| Chongqing Shi Yi Li Pharmaceuticals Technology Co., Ltd. romanized; Ma An Shan Feng Yuan Pharmaceutical Co., Ltd. romanized | CYHS2601822 | 2026/07/29 | Official source ↗ |
| Nang Kuang Pharmaceutical Co. Ltd; Hainan zhenyuanPharmaceutical Co. Ltd. | JYHZ2600163 | 2026/07/07 | Official source ↗ |
| Wuhan Ren Fu Pharma Co., Ltd. romanized; Sichuan Hui Yu Pharmaceutical Co., Ltd. romanized | CYHS2601473 | 2026/06/23 | Official source ↗ |
| Wuhan Ren Fu Pharma Co., Ltd. romanized; Sichuan Hui Yu Pharmaceutical Co., Ltd. romanized | CYHS2601472 | 2026/06/23 | Official source ↗ |
| Shandong Da Guan Pharmaceuticals Technology Co., Ltd. romanized; Yan Tai Dong Cheng Bei Fang Pharmaceutical Co., Ltd. romanized | CYHS2600447 | 2026/02/11 | Official source ↗ |
| Shandong Xin Hua Lu Kang Pharmaceuticals Co., Ltd. romanized; Hainan He Rui Pharmaceutical Co., Ltd. romanized | CYHS2503641 | 2025/10/14 | Official source ↗ |
| Chongqing Lai Mei Pharma Co., Ltd. romanized | CYHB2501569 | 2025/08/08 | Official source ↗ |
| Hainan Brilliant Pharmaceutical Co., Ltd.; Hainan He Rui Pharmaceutical Co., Ltd. romanized | CYHS2502446 | 2025/07/09 | Official source ↗ |
| Hainan Brilliant Pharmaceutical Co., Ltd.; Hainan He Rui Pharmaceutical Co., Ltd. romanized | CYHS2502445 | 2025/07/09 | Official source ↗ |
| Shu Mei Qi Chengdu Bio Technology Co., Ltd. romanized; Chengdu Tian Tai Shan Pharmaceutical Co., Ltd. romanized | CYHS2501816 | 2025/05/20 | Official source ↗ |
| Shu Mei Qi Chengdu Bio Technology Co., Ltd. romanized; Chengdu Tian Tai Shan Pharmaceutical Co., Ltd. romanized | CYHS2501815 | 2025/05/20 | Official source ↗ |
Generic-filing companies this year 4
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Nanjing Huang Long Bio Technology Co., Ltd. romanized; Ma An Shan Feng Yuan Pharmaceutical Co., Ltd. romanized | CYHS2601437 | 2026/06/17 | Official source ↗ |
| Chongqing Shi Yi Li Pharmaceuticals Technology Co., Ltd. romanized; Ma An Shan Feng Yuan Pharmaceutical Co., Ltd. romanized | CYHS2601822 | 2026/07/29 | Official source ↗ |
| Wuhan Ren Fu Pharma Co., Ltd. romanized; Sichuan Hui Yu Pharmaceutical Co., Ltd. romanized | CYHS2601473 | 2026/06/23 | Official source ↗ |
| Wuhan Ren Fu Pharma Co., Ltd. romanized; Sichuan Hui Yu Pharmaceutical Co., Ltd. romanized | CYHS2601472 | 2026/06/23 | Official source ↗ |
| Shandong Da Guan Pharmaceuticals Technology Co., Ltd. romanized; Yan Tai Dong Cheng Bei Fang Pharmaceutical Co., Ltd. romanized | CYHS2600447 | 2026/02/11 | Official source ↗ |
API companies with A status 1
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Henan Li Hua Pharmaceutical Co., Ltd. romanized | Y20170001669 | 2024/09/11 | Official source ↗ |
Trial registrations 2025/2026 —
Not loaded
Sources and dates
- FDA Orange Book
- 2026/11/06
- CDE acceptance and review
- 2026/11/13 06:42
- Chemical Drug Catalog
- 2026/11/13 06:39
- API registration records
- 2026/11/13 06:41
- NHSA drug code database
- 2026/10/23
- Trial registry
- 2026/11/13 08:09 · Incomplete coverage
Chinese counts use complete ingredient, dosage-form and route matches. Unmatched and partial rows show name-source matching only and make no finding about Chinese approvals or filings. Trials cover registration-number years 2025/2026 only.
Formulation crosswalk to INJECTABLE / INJECTION, based on the Chinese Pharmacopoeia general formulation provisions, rule CHP-FORM-088. Chinese Pharmacopoeia general chapter 0102
Comparison generated: 2026/11/13 18:41 · openFDA Orange Book ↗
Name and dosage-form matching sources
- NMPA reference-product directory, Shaanxi MPA republication ↗ · 55-71 · 2022/09/13
- Chinese Pharmacopoeia 2025, formulation chapter; site crosswalk ↗ · See source
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy